Data gathered: February 1
AI Stock Analysis - Esperion Therapeutics (ESPR)
Analysis generated March 24, 2024. Powered by Chat GPT.
Esperion Therapeutics is a biopharmaceutical company dedicated to the research, development, and commercialization of therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C) in the backdrop of statin intolerance or insufficient treatment response. The company's flagship products are designed to address significant needs in the lipid management space. The drug development focus on specific patient subsets within the broader cardiovascular disease market is crucial, as these patients often have limited options available.
Stock Alerts - Esperion Therapeutics (ESPR)
 |
Esperion Therapeutics | January 27 Price is down by -5.2% in the last 24h. |
|
Esperion Therapeutics | January 24 Price is up by 5.8% in the last 24h. |
|
Esperion Therapeutics | January 23 Price is down by -5% in the last 24h. |
|
Esperion Therapeutics | January 22 Insider Alert: Halladay Benjamin is selling shares |
Alternative Data for Esperion Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 3 | Sign up | Sign up | Sign up |
| Sentiment | 90 | Sign up | Sign up | Sign up |
| Webpage traffic | 6,000 | Sign up | Sign up | Sign up |
| Employee Rating | 72 | Sign up | Sign up | Sign up |
| Google Trends | 10 | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 57 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 8,921 | Sign up | Sign up | Sign up |
| Twitter Followers | 2,079 | Sign up | Sign up | Sign up |
| Twitter Mentions | 8 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 61 | Sign up | Sign up | Sign up |
| Linkedin Employees | 339 | Sign up | Sign up | Sign up |
About Esperion Therapeutics
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol.
| Price | $1.79 |
| Target Price | Sign up |
| Volume | 9,380,000 |
| Market Cap | $357M |
| Year Range | $1.61 - $3.83 |
| Dividend Yield | 0% |
| Analyst Rating | 75% buy |
| Industry | Drug Manufacturers |
In the news
 |
Equities Analysts Offer Predictions for ESPR FY2028 EarningsJanuary 27 - ETF Daily News |
|
Cantor Fitzgerald Estimates ESPR FY2025 EarningsJanuary 22 - ETF Daily News |
|
Barclays PLC Has $510,000 Stock Holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR)January 18 - ETF Daily News |
 |
Esperion Therapeutics’ (ESPR) “Buy” Rating Reiterated at HC WainwrightJanuary 12 - ETF Daily News |
|
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives $8.13 Consensus Target Price from AnalystsDecember 23 - ETF Daily News |
Esperion Therapeutics, Inc.(NasdaqGM: ESPR) added to S&P Pharmaceuticals Select Industry IndexDecember 22 - Finnhub |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 52M | 40M | 12M | -30M | -14M | -0.150 |
| Q2 '24 | 21M | 44M | -24M | -62M | -48M | -0.330 |
| Q1 '24 | 124M | 42M | 82M | 61M | 75M | 0.340 |
| Q4 '23 | 17M | 45M | -28M | -56M | -41M | -0.500 |
| Q3 '23 | 19M | 33M | -14M | -41M | -28M | -0.370 |
Insider Transactions View All
| Halladay Benjamin filed to sell 240,682 shares at $2.3. January 21 '25 |
| Warren Eric filed to sell 159,998 shares at $2.3. January 21 '25 |
| Warren Eric filed to sell 160,121 shares at $2.4. December 18 '24 |
| Halladay Benjamin filed to sell 240,691 shares at $2.4. December 18 '24 |
| Koenig Sheldon L. filed to sell 739,819 shares at $2.5. December 18 '24 |
Similar companies
| Company | Price | AI Score | |
|---|---|---|---|
 |
Johnson & JohnsonJNJ |
$152.15 0% | 48 |
 |
Eli Lilly and CompanyLLY |
$811.08 0% | 56 |
 |
PfizerPFE |
$26.52 0% | 42 |
 |
AstrazenecaAZN |
$70.76 0% | 49 |
 |
AbbVieABBV |
$183.9 0% | 52 |
Read more about Esperion Therapeutics (ESPR) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Esperion Therapeutics?
The Market Cap of Esperion Therapeutics is $357M.
What is the current stock price of Esperion Therapeutics?
Currently, the price of one share of Esperion Therapeutics stock is $1.79.
How can I analyze the ESPR stock price chart for investment decisions?
The ESPR stock price chart above provides a comprehensive visual representation of Esperion Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Esperion Therapeutics shares. Our platform offers an up-to-date ESPR stock price chart, along with technical data analysis and alternative data insights.
Does ESPR offer dividends to its shareholders?
As of our latest update, Esperion Therapeutics (ESPR) does not offer dividends to its shareholders. Investors interested in Esperion Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Esperion Therapeutics?
Some of the similar stocks of Esperion Therapeutics are Johnson & Johnson, Eli Lilly and Company, Pfizer, Astrazeneca, and AbbVie.
.